The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by Chardan Capital on November 15, 2024. The analyst firm set a price target for $11.00 expecting CGTX to rise to within 12 months (a possible 2590.80% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by Chardan Capital, and Cognition Therapeutics maintained their buy rating.

There is no last upgrade for Cognition Therapeutics

The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a maintained with a price target of $11.00 to $11.00. The current price Cognition Therapeutics (CGTX) is trading at is $0.41, which is out of the analyst’s predicted range.